Autologous bone marrow transplantation for non-Hodgkin's lymphoma.
Autologous bone marrow transplantation (ABMT) is now so widely applied in the treatment of relapsed high- and intermediate-grade non-Hodgkin's lymphoma (NHL) that it is very important to analyse the evidence on which this practice is based and ask in precise terms what the place of this technique should be. This article will review the data that have been published and discuss the randomised studies now in progress. The possible use of ABMT in other areas such as consolidation of remission and its use in low-grade lymphoma will also be examined. The EBMT data quoted are taken from the 1990 review of the register for ABMT in malignant lymphoma which was presented to the XVIth meeting of the EBMT in the Hague in 1990.
McMillan
A K
AK
Department of Haematology, University College and Middlesex School of Medicine London, UK.
Goldstone
A H
AH
D016026:Bone Marrow Transplantation / Q000009:adverse effects; D003131:Combined Modality Therapy; D004351:Drug Resistance; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000401:mortality / Q000601:surgery*; D014182:Transplantation, Autologous